Literatuur
- Brose M. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384:319-28
- Brose M. et al. 953 PD - Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: an exploratory crossover adjustment analyses. Annals of Oncology 27 (supplement 6): vi328–vi350, 2016
- Schlumberger M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England Journal of Medicine 2015; 372:621-30
- Drilon A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. The New England Journal of Medicine 2018; 378:731-9
- Wells SA. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012; 30:134-41
- Elisei R. et al. Cabozantinib in progressive medullary thyroid cancer. Journal of Clinical Oncology 2013; 31:3639-46
- Schlumberger M. et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Annals of Oncology 2017; 28:2813-9
- Subbiah V. et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. Journal of Clinical Oncology 2018; 36:7-13
- Smallridge RC et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012; 22:1104-39
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over schildkliercarcinoom.
Richtlijnen
Ga naar de richtlijn Schildkliercarcinoom in de FMS richtlijnendatabase.